These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32081234)

  • 1. Pathology and Multimodality Imaging of Acute and Chronic Femoral Stenting in Humans.
    Kuntz SH; Torii S; Jinnouchi H; Cornelissen A; Sakamoto A; Sato Y; Kutyna M; Romero ME; Lejay A; Schwein A; Bonnin E; Finn AV; Chakfé N; Virmani R
    JACC Cardiovasc Interv; 2020 Feb; 13(4):418-427. PubMed ID: 32081234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stent fractures after superficial femoral artery stenting: risk factors and impact on patency.
    Lin Y; Tang X; Fu W; Kovach R; George JC; Guo D
    J Endovasc Ther; 2015 Jun; 22(3):319-26. PubMed ID: 25862365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Vascular Calcifications on Long Femoropopliteal Stenting Outcomes.
    Kaladji A; Vent PA; Danvin A; Chaillou P; Costargent A; Guyomarch B; Quillard T; Gouëffic Y
    Ann Vasc Surg; 2018 Feb; 47():170-178. PubMed ID: 28893701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis.
    Gasior P; Cheng Y; Valencia AF; McGregor J; Conditt GB; Kaluza GL; Granada JF
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28487355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infrapopliteal Anatomic Severity and Delayed Wound Healing in Patients With Chronic Limb-Threatening Ischemia in the Era of the Global Limb Anatomic Staging System.
    Hata Y; Iida O; Takahara M; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Okuno S; Matsuda Y; Mano T
    J Endovasc Ther; 2020 Aug; 27(4):641-646. PubMed ID: 32571134
    [No Abstract]   [Full Text] [Related]  

  • 6. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iliofemoral endarterectomy associated with systematic iliac stent grafting for the treatment of severe iliofemoral occlusive disease.
    Maitrias P; Deltombe G; Molin V; Reix T
    J Vasc Surg; 2017 Feb; 65(2):406-413. PubMed ID: 27693029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Algorithm for the Use of Embolic Protection During Atherectomy for Femoral Popliteal Lesions.
    Krishnan P; Tarricone A; Purushothaman KR; Purushothaman M; Vasquez M; Kovacic J; Baber U; Kapur V; Gujja K; Kini A; Sharma S
    JACC Cardiovasc Interv; 2017 Feb; 10(4):403-410. PubMed ID: 28231909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative CT-scan-based sizing and in-stent restenosis in peripheral endovascular revascularizations.
    Kaladji A; Giovannetti M; Pascot R; Clochard E; Daoudal A; Lucas A; Cardon A
    Vascular; 2017 Oct; 25(5):504-513. PubMed ID: 28330432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall Healing after IMplantation of drug Eluting peripheral stent in Japanese patients with the Infra inguinal lesion: serial angioscopic observation).
    Tsukiyama Y; Shinke T; Ishihara T; Otake H; Terashita D; Kozuki A; Fukunaga M; Zen K; Horimatsu T; Fujii K; Shite J; Uematsu M; Takahara M; Iida O; Nanto S; Hirata KI
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1777-1784. PubMed ID: 31201589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of statin therapy with the primary patency of femoral and popliteal artery stents.
    de Grijs D; Teixeira P; Katz S
    J Vasc Surg; 2018 May; 67(5):1472-1479. PubMed ID: 29224939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease.
    Ansel GM; Jaff MR; Popma JJ; Battisti AJ; Lottes AE; Harnish P; Dake MD
    J Endovasc Ther; 2017 Aug; 24(4):499-503. PubMed ID: 28485182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Failed Crossover Stenting across the Ostium of the Deep Femoral Artery: Report of 2 Cases.
    Iwasaki T; Ogino H; Nishibe T
    Ann Vasc Surg; 2016 Apr; 32():128.e1-5. PubMed ID: 26724426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
    Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
    JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
    J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
    Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lumen Gain After Endovascular Therapy in Calcified Superficial Femoral Artery Occlusive Disease Assessed by Intravascular Ultrasound (CODE Study).
    Fujihara M; Kozuki A; Tsubakimoto Y; Takahara M; Shintani Y; Fukunaga M; Iwasaki Y; Nakama T; Yokoi Y
    J Endovasc Ther; 2019 Jun; 26(3):322-330. PubMed ID: 30873909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.